-- 再鼎醫藥（ZLAB）週五表示，其正在進行的zocilurtatug pelitecan I期臨床試驗數據顯示，在小細胞肺癌腦轉移患者中，顱內客觀緩解率達到53.7%。 該公司在聲明中表示，這些研究結果表明，zoci候選藥物能夠誘導顱內病灶消退並縮小腫瘤體積，相關結果將在聖地牙哥舉行的美國癌症研究協會年會上發表。 該公司也表示，這種潛在的zoci藥物偶聯物也展現出良好的安全性，大多數不良事件為低度。 該公司也表示，其Ib/II期臨床試驗數據也顯示，zocilurtatug pelitecan在肺外神經內分泌癌患者中具有抗腫瘤活性，客觀緩解率為38.2%。
Price: $24.06, Change: $+0.56, Percent Change: +2.38%
FINEOS (ASX:FCL) reported first-quarter customer cash receipts of 56.5 million euros, up 9.3% year-on-year, driven by subscription fee revenues invoiced in January, according to a Monday Australian bourse filing.The company recorded customer cash receipts of 51.7 million euros for the three months ending March 31, 2025, an earlier filing showed.Exchange rate movements during the quarter had a positive impact of 1 million euros on the cash balance.The company's full-year revenue guidance remains in the range of 147 million euros to 152 million euros.The company's shares fell 1% in recent Monday trade.
Changyu Holding (SHA:603407) priced its initial public offering on the Shanghai Stock Exchange of 41 million shares at 13.86 yuan apiece to raise 568.3 million yuan, according to a weekend filing on the bourse.Proceeds will be invested in the company's zirconium oxychloride and deep-processing project, a nylon elastomer products project, and a bioceramics and functional ceramics products project.
Shaanxi Coal Industry's (SHA:601225) net profit attributable to shareholders in 2025 dropped 25% year on year to 16.8 billion yuan, or 1.73 yuan per share, according to a Saturday filing on the Shanghai bourse.The coal miner's share dropped 4% during the morning trade.The attributable profit a year earlier was 22.4 billion yuan, or 2.31 yuan per share.Operating revenue fell 14% to 158.2 billion yuan from 184.1 billion yuan in the previous year.